Month: January 2025

TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) — MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, is pleased to announce that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”) is now providing its remote health monitoring system, REMONY, and charging-free smart tracker device, MOTHER Bracelet®︎, to the Electronics Division of TOPPAN Inc. (Tokyo Stock Exchange: 7911). In recent years, employee health management has shifted from being an individual’s responsibility to becoming one of the key priorities for companies. Since their founding, TOPPAN has consistently undertaken various initiatives to ensure the physical and mental well-being of their employees based on the core philosophy of respect for human beings....

WEST PALM BEACH, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (“Sunrise Realty” or “the Company”) (Nasdaq: SUNS), an institutional lender that originates and funds loans to commercial real estate projects in the Southern United States, today announced that it has launched an underwritten public offering (the “Offering”) of 5,500,000 shares of its common stock. Sunrise Realty intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 825,000 shares of common stock. Sunrise Realty intends to use the net proceeds from the Offering to fund loans related to unfunded commitments to its existing borrowers, to originate and participate in commercial loans to commercial real estate projects in the Southern United States that are consistent with its investment strategy, and for...

DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix Operations, Inc. (“Isomedix”), a subsidiary of the Company, ended in a mistrial on January 17, 2025. The case is pending in the Circuit Court of Cook County, Illinois, and involves claims by an individual plaintiff that ethylene oxide emissions from a sterilization facility in Waukegan, Illinois, caused personal injury. Isomedix owned and operated the facility from 2005 to 2008. The Court declared a mistrial at Plaintiff’s request during jury deliberations when dismissal of one of the jurors reduced the jury to fewer than twelve. The Court will schedule the case for re-trial at a later date. Isomedix intends to continue to vigorously...

– Milton Cooper to Transition to Chairman Emeritus – – Richard Saltzman to Become Independent Chairman of the Board – – Nancy Lashine and Ross Cooper Join the Board of Directors – JERICHO, N.Y., Jan. 21, 2025 (GLOBE NEWSWIRE) — Kimco Realty Corporation (NYSE: KIM) (the “Company”) has announced the following changes to the Company’s Board of Directors: After more than 60 years of leadership, Mr. Milton Cooper will retire as Executive Chairman of the Company and Kimco Realty OP, LLC (“Kimco OP”) at the 2025 Annual Meeting of Stockholders. Upon Mr. Cooper’s retirement as Executive Chairman of the Company and Kimco OP, Richard Saltzman will become the Independent Chairman of the Board of Directors, Mary Hogan Preusse will conclude her service as Lead Independent Director while remaining a member of the Board, and Milton Cooper will...

Global Trade Intelligence and Global Trade Analytics are Top Technologies Expected to Deliver Business Value ATLANTA and LONDON, Jan. 21, 2025 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, released findings from its study What Companies are Doing to Tackle Escalating Global Supply Chain Challenges. The study shows that 74% of the supply chain and logistics leaders surveyed view technology as fundamental or highly important to their organization’s growth strategy in the face of rising global trade challenges, such as tariffs and trade barriers, supply chain disruptions and geopolitical instability. This number jumps to 88% for companies expecting greater than 15% growth over the next two years. In addition, 59% consider technology as extremely...

Combines Pioneering Bioleum Refining Process with High Yield Energy Crops to Create Perpetual “Drop-In Permian Basins” with the Capacity for Domestic Energy Dominance OKLAHOMA CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE American: LODE) today announced that its subsidiary, Comstock Fuels Corporation (“Comstock Fuels”), a leader in advanced lignocellulosic technologies, has executed an agreement with Hexas Biomass Inc. (“Hexas”), securing exclusive rights to Hexas’ intellectual properties in liquid fuels applications, subject to certain pre-existing agreements and relationships. Domestic Energy Dominance Comstock Fuels delivers advanced lignocellulosic biomass refining solutions that set industry benchmarks for production of renewable Bioleum™ fuels at market-leading yields of up to 140 gallons per dry metric...

VANCOUVER, British Columbia and LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network and medical platform and VSDHOne, its innovative telehealth and e-commerce platform developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), today announced the launch of a D2C Digital Health Accelerator program. This initiative will invest up to $10 million in the form of cash, a comprehensive suite of VSDHOne resources, services and/or company shares to support emerging healthcare brands poised to improve patient care across the United States. This program directly addresses the massive opportunity in the US healthcare system, projected to reach $7.2 trillion by 2031, according...

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. “We believe the true value of JNJ-1900 (NBTXR3)...